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Thursday, October 31
1:00 pm – 6:00 pm Registration, Poster Set- Up
6:00 pm – 7:00 pm Welcome Reception
Friday, November 1
7:00 am Registration, Continental Breakfast
7:00 am Executive Committee Meeting
8:00 am Welcome, Opening Announcements: Lee Helman, CTOS President & George Demetri,
Program Chair
8:15 am HOW WE  IMAGE  SARCOMAS  AND  APPROACH THE  MANAGEMENT  OF 
PATIENTS WITH SARCOMAS
8:15 am #39 The Role Of Ultrasonography To Evaluate Chest Wall Sarcomas
Antonio Briccoli, Italy
8:30 am #78  High-resolution  Intravascular  Ultrasonography  To  Assess Vessel-
invasiveness Of Soft Tissue Sarcoma
Peter Hohenberger, Germany
8:45 am #27  Predictive Value  Of  Gadolinium  Enhancement  In  Differentiating 
Atypical Lipomas (well-differentiated Liposarcomas) From Benign Fatty 
Tumors
Matthew J. Panzarella, USA
9:00 am #61 Fdg- Positron Emission Tomography (pet) In Staging And Managing 
Patients With Soft Tissue Sarcomas
Thomas F. DeLaney, USA
9:15 am #31 Fluorodeoxyglucose Uptake In Adult Soft Tissue Sarcoma Predicts 
Risk Of Recurrence After Chemotherapy
Scott M Schuetze, USA
9:30 am #48 Should Soft Tissue Sarcomas Be Treated At A Specialist Centre?
Robert Grimer, UK
9:45 am #55 Positive Margins After Attempted Wide Excision Of A Soft Tissue 
Sarcoma: Is Further Excision Necessary?
Edward Y. Cheng, USA
10:00 am Discussion
10:15 am Coffee Break, Poster Viewing
10:45 am NEW DIAGNOSTIC TOOLS – cDNA MICROARRAY DATA AND 
INTERPRETATION
10:45 am #73 Microarray Analysis Of Malignant Fibrous Histiocytoma
Jay S Wunder, Canada
11:00 am #49 Genome-wide Analysis Of Gene Expression In Synovial Sarcoma 
Using A Cdna Microarray
Junya Toguchida, Japan
11:15 am #24 Differential Gene Expression In Leiomyosarcoma.
Keith M Skubitz, USA
11:30 am #35  Antisense  Inhibition  Of  Hyaluronan  Synthase-2  In  Human 
Osteosarcoma  Cell  Line, Mg-63, Inhibits  Hyaluronan  Retention And 
Tumorigenicity Of The Cells
Yoshihiro Nishida, Japan
11:45 am #22 Neoplastic Transformation Of  Primary Human Osteoblasts Over-
expressing The Met Receptor By Means Of Transduction With Lentiviral 
Vectors
Riccardo Ferracini, Italy
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12:00 pm #71 (Young Investigator Award Winner) Targeting Met Oncogene In 
Human  Osteosarcoma  By  K-252a  Tyrosine-kinase  Inhibitor: A  New 
Therapeutic Approach
So￿ a Avnet, Italy
12:15 pm Discussion
12:30 pm – 1:45 pm Lunch, Poster Viewing
12:30 pm – 1:45 pm Board of Directors Meeting
1:45 pm NEW LABORATORY AND CLINICAL TRIAL DATA
Amifostine and Ifosfamide
1:45 pm #46 Differential Effects Of The Radioprotectant Amifostine On Ewing’s 
Sarcoma And Human Monocytes In Culture
Matthew J. Allen, USA
2:00 pm #37 A Randomized  Trial Of Amifostine With High-dose Alkylator Therapy 
In Ewing Sarcoma: A Children’s Oncology Group Trial (p9457)
Mark L Bernstein, Canada
2:15 pm #20  Randomised  Phase  3 Trial  Of Two  Investigational  Schedules  Of 
Ifosfamide Versus Standard Dose Doxorubicin In Patients With Advanced 
Or Metastatic Soft Tissue Sarcoma (asts).
Paul Lorigan, UK
Cartilagenous Tumors
2:30 pm #17 Expression Of The Ihh/pthrp And Bmp Receptors Has Diagnostic 
Relevance In Cartilagineous Lesions
Luca Sangiorgi, Italy
2:45 pm #19 Dedifferentiated Chondrosarcoma: Updated Outcomes  With Current 
Treatment Approaches As Compared To Those Prior To 1984
Ian Douglas Dickey, USA
Desmoid Tumors
3:00 pm #50 Desmoid Tumors. A Clinical Review Of 30 Patients With More Than 
20 Years Follow-up
Mikael Dalén, Sweden
3:15 pm #30  Unexpected  Severe  Toxicity  Of  Low  Dose  Metothrexate  And 
Vinblastine In Patients With Desmoid Tumours
Bert van Geel,The Netherlands
Radiotherapy Dosing and Delivery
3:30 pm #33 Higher Postoperative Radiation Dose Improves The Local Control 
Rate For Patients With Positive Surgical Margins And Locally Recurrent 
Soft Tissue Sarcoma
Matthew T Ballo, USA
3:45 pm #76 Advantages Of Proton Beams In Treatment Pelvic Sarcomas
Herman Suit, USA
4:00 pm Coffee Break, Poster Viewing
4:00 pm NEW ISSUES IN THE USE OF IMATINIB (Gleevec/Glivec) in GIST and 
OTHER SARCOMAS
4:00 pm #29 Phase 2 Trial With Imatinib (glivec, Sti571) In Patients With Gasto-
intestinal Stromal Tumors (gist):Activity Results After 1 Year. A Study Of 
The Eortc Soft Tissue And Bone Sarcoma Group (stbsg)
Jaap Verweij,The NetherlandsCTOS abstracts S61
4:15 pm #25  (Young  Investigator  Award  Winner) Molecular Targeting  Of 
PDGF-R By Imatinib Mesylate In Dermato￿ brosarcoma Protuberans
Scott M Schuetze, USA
4:30 pm #57  Gleevec  Therapy  In  C-kit  Negative  Soft  Tissue  Sarcomas: A 
Molecular Rationale
Dafydd Gareth Thomas, USA
4:45 pm Discussion
5:15 pm Members’ Business Meeting
7:00 pm  CTOS Reception & Dinner Banquet
Saturday, November 2
6:30 am Registration, Continental Breakfast
7:30 am NEW DATA IN SARCOMA SURGERY
7:30 am #40 Approach To Prosthetic Reconstruction In Sternal Sarcoma
Michele Rocca, Italy
7:45 am #42 Autobiological Reconstruction With Preserved Joint Function After 
Surgical Treatment Of Bone Sarcomas In Children
Michele Rocca, Sweden
8:00 am #74  Endoprosthetic  Replacement  Of  Distal  Humerus  After  Tumor 
Resection
Fabrice Fiorenza, France
8:15 am #26 Survivorship Analysis Of 141 Modular Metallic Endoprostheses
Mark C. Gebhardt, USA
8:30 am #59  Low  Complication  Rate  With  Limb-sparing  Resection  And 
Endoprosthetic Reconstruction: Survival Analysis Of 251  Patients And 
Analysis Of 20-year Experience
Felasfa M Wodajo, USA
8:45 am #77 Is There A Case For A Randomized Clinical Trial For Treatment Of 
Giant Cell Tumours?
Robert Grimer, UK
9:00 am NINA AXELRAD KEYNOTE LECTURE (supported by the Nina Axelrad Fund)
Dr. Herman Suit:
Perspectives on the Use and Future of Radiation Therapy for Sarcomas
10:00 am Coffee Break, Poster Viewing
10:30 am THE INTERFACE BETWEEN GENETICS AND SARCOMAS:
MINI-SYMPOSIUM ON NF1, Neuro￿ bromatosis, and Malignant Peripheral 
Nerve Sheath Tumors
12:30 pm Lunch, Poster Viewing
1:30 pm COLLABORATION AND INNOVATION –
Support and Stimulation of Sarcoma Research
– The view from the US NCI
– The view from the EORTC, Scandinavian, Italian, French, and other Sarcoma 
Groups
2:30 pm THE VIEW FROM SARCOMA PATIENT AND FAMILY ADVOCACY GROUPS
GIST – The Life Raft Group
Sarcoma Foundation of America
Sarcoma Alliance
3:30 pm Coffee Break, Poster Viewing
4:00 pm MICRO-SYMPOSIUM: Clinical Trial Statistical Issues for Sarcomas
5:00 pm Adjourn